Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azacitidine - Pfizer

Drug Profile

Azacitidine - Pfizer

Alternative Names: 5-azacytidine; Aza-C; Azacytidine; BMS-986345; CC-486; Ladakamycin; NS-17; NSC-102816; Onureg; Oral-Aza; U-18496; VIDAZA; Vidaza

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacia Corporation
  • Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb; Celgene Corporation; Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Kirby Institute for infection and immunity in society; Medical University of South Carolina; Nippon Shinyaku; Pfizer; University Hospital Regensburg; University of Bologna; University of California, San Diego; University of Colorado at Denver; University of Kansas Medical Center; University of Leipzig; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Myeloid leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase III T-cell lymphoma
  • Phase II Fallopian tube cancer; Graft-versus-host disease; HER2 negative breast cancer; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer; Peripheral T-cell lymphoma; Peritoneal cancer
  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Large granular lymphocytic leukaemia; Lymphoid leukaemia; Renal cancer; Solid tumours
  • No development reported Lymphoma; Multiple myeloma

Most Recent Events

  • 30 Jan 2024 Medical University of South Carolina and Celgene completes a phase-I trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03450343)
  • 08 Jan 2024 Celgene completes a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in Australia and USA (PO) (NCT04887857)
  • 31 Dec 2023 Beigene and Celgene Corporation terminates the license and supply agreement covering REVLIMID and VIDAZA as part of the settlement agreement
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top